Specific inhibition of bile acid transport alters plasma lipids and GLP-1

BACKGROUND: Elobixibat is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor in development against chronic constipation (CC) and constipation-predominant Irritable Bowel Syndrome (IBS-C). CC is associated with an increased risk for cardiovascular disease and type2 diabetes melli...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudling, Mats, Camilleri, Michael, Graffner, Hans, Holst, Jens Juul, Rikner, Leif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511433/
https://www.ncbi.nlm.nih.gov/pubmed/26197999
http://dx.doi.org/10.1186/s12872-015-0070-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511433/
https://www.ncbi.nlm.nih.gov/pubmed/26197999
http://dx.doi.org/10.1186/s12872-015-0070-9

Ejemplares similares